Chiklita ad

Showing posts with label Radiotherapy. Show all posts
Showing posts with label Radiotherapy. Show all posts

Tuesday, 30 January 2018

Oestrogen changes neuroblastoma cells into neurons


The female sex hormone oestrogen can perform an important role in neuroblastoma, a form of cancer mainly affecting young children. In laboratory experiments, researchers at Karolinska Institutet in Sweden demonstrate that oestrogen treatment and overexpression of the oestrogen receptor cause malignant neuroblastoma cells to mature into neuron-like cells.

Neuroblastoma forms in the peripheral nervous system and is one of the most common forms of solid cancer in young children. The disease mainly affects babies and young children, and while in some cases the tumours can disappear of their own accord, the majority are aggressive, metastasising cancer tumours that are resistant to modern combinations of surgery, radiotherapy and intensive chemotherapy.

The most aggressive forms of neuroblastoma are often associated with a more active MYCN gene, which drives tumour cell growth and spread and inhibits the maturation of the cells. Researchers focus on the activity of this gene and how it relates to neuroblastoma. MYCN is often seen only as a marker for a poor prognosis, but it's critical to the disease and is a possible target for new drugs.

In a previous study, the group discovered that activation of MYCN results in the formation of specific microRNAs, which are relatively small RNA molecules that regulate proteins. Some of these microRNAs disable the oestrogen receptor ERalpha. The present study shows that the inhibition of these microRNA molecules or oestrogen therapy in combination with an overexpression of the oestrogen receptor can cause aggressive neuroblastoma cells with MYCN activation to mature into neuron-like cells which behave more like normal cells.

The researchers studied tumour tissue from patients, cultivated human tumour cells and tumours in mouse models for neuroblastoma. In the mice, the neuron-like cells did not grow as quickly as the original cancer cells, and analyses of the tumour tissue from patients show that those with a high level of the oestrogen receptor have a better survival rate than those with a low. Oestrogen could be a therapeutic method for patients who express high levels of the oestrogen receptor. Another therapy could involve deregulating MYCN or upregulating the oestrogen receptor and then treating with oestrogen.
          haleplushearty.blogspot.com

Monday, 8 May 2017

Symptoms of pancreatic cancer

The pancreas is a large gland that is part of the digestive system.
In the early stages of cancer, a tumour in the pancreas doesn't usually cause any symptoms, which can make it difficult to diagnose.

Some people in the early stages of the disease can experience abdominal pain, changes of bowel habits, nausea and vomiting, jaundice, diabetes, back pain and weight loss.

Survival rates for pancreatic cancer remain low, with most patients given months rather than years to live,” said Dr Francesco Cellini, radiation oncologist.

The study retrospectively analysed 514 patients from Europe and the US diagnosed when their tumours had not spread and could be removed by surgery.

Following surgery, all the patients had been treated with chemotherapy combined with radiotherapy and followed up for an average of 20 months.

For patients with early stage tumours, standard treatment is surgery followed by chemotherapy, sometimes with radiotherapy.

For later-stage disease, patients are treated with chemotherapy, which may be combined with palliative radiotherapy as their disease progresses.